LEChENIE YaZVENNOGO KOLITA LEGKOGO I SREDNETYaZhELOGO TEChENIYa
- Authors: Belousova E.A1, Nikitina N.V1, Tsodikova O.M1
-
Affiliations:
- Issue: No 2 (2013)
- Pages: 42-46
- Section: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/280241
- ID: 280241
Cite item
Open Access
Access granted
Abstract
Distal forms of ulcerative colitis, including proctitis, are the major problem of treatment of exacerbations of ulcerative colitis with aminosalicylates. This is due to the fact that release of the active substance during application of traditional drug mesalazine occurs in the more proximal parts of the colon. The article considers the potentials for the use of new Multi-Matrix system formulation of mesalazine (Mezavant) with prolonged release of the active substance, which provides a more homogenous distribution of the active substance using a single daily dose. This increases the effectiveness of treatment of exacerbations of ulcerative colitis, especially its distal forms, and reduces the risk of relapses.
Full Text
References
- Белоусова Е.А. Язвенный колит и болезнь Крона. М., 2002. С. 6-34, 48-112.
- Адлер Г. Болезнь Крона и язвенный колит. ГЕОТАР-МЕД. 2001. 500 c.
- Румянцев В.Г. Язвенный колит: руководство для врачей. М, 2009. 424 с.
- Stange EF, Travis SPL, Vermeire S, et al. European evidence based consensus on the diagnostic and management of Ulcerative colitis: definitions and diagnostic. J Crohns Colitis 2008;2:1-23.
- Silverberg M, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serologic classification of Inflammatory Bowel Disease: report of a working party of the 2005 Montreal World Congress of Gstroenterology. Can J Gastroenterol 2005;19(A):5-36.
- Truelove S, Witts L. Cortisone in ulcerative colitis. Br Med J 1955;2:1041-48.
- Rachmilewitz D. Prostaglandins, leukotrienes, platelet activating factor and nitric oxide. Inflammatory bowel disease - From Bench to Bedside. International Symposium on IBD, 1996:133-38.
- Zimmerman M. Cytikines and mechanism of action of glucocorticoids and aminosalicylates in the treatment of ulcerative colitis. Aliment Pharmacol Ther1996;10(2):93-8.
- Zeitz M. Role of immunological mechanisms in Inflammatory bowel Disease. Innovative concepts in Inflammatory bowel Disease. International symposium on IBD, 1998:33-8.
- Ситкин С.И. Возможность повышения терапии и комплаенса у пациентов с воспалительными заболеваниями кишечника с помощью инновационных препаратов перорального месалазина // Гастроэнтерология С.-Петербурга 2011. № 1. С. 1-5.
- Travis E, Stange M, Lemman M, Oresland T, et al. European evidence based consensus on the management of Ulcerative colitis: current management. J Crohns Colitis 2008;2:24-62.
- Yen L, Klingman D, Hodgkins P. Improved adherence and persistence with once-daily Lialda® therapy for ulcerative colitis in the United States: retrospective analysis of a multiplan claims data-base. Annual Meeting of the American College of тивности между старыми и новыми пероральными препаратами месалази-на при лечении активного распространенного (тотального и левостороннего) ЯК нет. Критерием выбора препарата является не столько его эффективность, сколько уровень и протяженность высвобождения месалазина в толстой кишке, кратность приема в сутки, стоимость, доступность и рекомендации национальных руководств [11]. Gastroenterology, San Antonio, USA; October 2010.
- Prantera C, Viscido A, Biancone L, et al. A new oral delivery system for 5-ASA: preliminary clinical findings for MMX. Inflamm Bowel Dis 2005;11(5):421-27.
- Kamm M, Lichtenstein G, Sandborn W, et al. Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis. Gut 2008;57:893-902.
- Kane S, Katz S, Jamal M, et al. Strategies in Maintenance for Patients receiving Long-term Therapy (SIMPLE): A Study of MMX mesalazine for the Long-term Maintenance of Quiescent ulcerative colitis. Inflamm Bowel Dis 2012;18:1026-33.
- Brunner М, Assandri R, Kletter K, et al. Gastrointestinal transit and 5-ASA release from a new mesalazine extended-release formulation. Aliment Pharmacol Ther 2003;17:395-402.
- Kamm M, Sandborn W, Gassull M, et al. Once-Daily, High Concentration MMX Mesalazine in Active Ulcerative Colitis. Gastroenterology 2007;132:66-75.
Supplementary files
